Received Sep 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | IM |
Bronchiectasis; This spontaneous case was reported by a consumer and describes the occurrence of BRONCHIECTASIS (Bronchiectasis) in a 77-year-old female patient who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. Concurrent medical conditions included Immunocompromised. On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced BRONCHIECTASIS (Bronchiectasis) (seriousness criterion medically significant). At the time of the report, BRONCHIECTASIS (Bronchiectasis) outcome was unknown. The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) was unknown. No concomitant medications were reported. The patient had bronchiectasis and was immunocompromised. She had always received the Moderna vaccines and was happy with it. No treatment medications were reported. It was unknown if the patient experienced any additional symptoms or events.; Reporter's Comments: The event BRONCHIECTASIS is assessed as not related due to nature of the event and lack of biological plausibility. Additionally, no temporal relationship was established, and the patient had a history of immunocompromise, which may predispose to respiratory conditions independently of vaccination. The benefit-risk relationship of product is not affected by this report.
Immunocompromised